Anonymous View
Report Abuse Share Tor Link
Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool

Morpheus8 Logo

News provided by

InMode Ltd.

09 Sep, 2026, 15:05 IDT

Share this article

Share toX

Share this article

Share toX

IRVINE, Calif., Sept. 9, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announces the launch of Morpheus8 Cool, the next evolution of its renowned Morpheus8 technology. Available exclusively on the new expandable Morpheus8MAX platform, Morpheus8 Cool advances radiofrequency (RF) microneedling with enhanced comfort, precision, control, and safety.

Recognized as the world's #1 RF microneedling procedure, Morpheus8 is establishing a new industry standard with Morpheus8 Cool. The new handpiece and large-surface cooling tip feature game-changing Cool Comfort Technology, intelligently managing the thermal profile to elevate the treatment experience.  Morpheus8 Cool also features a new interactive user interface for enhanced control and safety.  Practitioners can select Guided Mode, with preset, clinically effective parameters that support consistent, repeatable outcomes, or Manual Mode for fully customizable settings.

"Developed in response to feedback from our providers, Guided Mode within the Morpheus8MAX platform offers greater versatility across their practices," said Dr. Michael Kreindel, InMode Chief Technology Officer and co-founder. "Its intuitive design gives practitioners greater flexibility to tailor treatments to each patient's skin concerns and anatomy while delivering the remarkable results patients and providers have come to expect from Morpheus8."

"Morpheus8 Cool addresses an important challenge in aesthetics: how to make a proven, successful technology even better," said Dr. Eran Krieger, Chief Medical Officer at InMode. "By cooling the skin's surface while treating the targeted tissue, we preserve the remodeling effect without compromising treatment. We are not changing the treatment—we are elevating the patient experience."

"The excitement surrounding Morpheus8 Cool was undeniable when we introduced it at our Insider Summit in Las Vegas," said Michael Dennison, InMode President, North America. "Providers immediately recognized the value of greater comfort, precision, and control, and the enthusiastic response reinforced the strong demand for this next evolution of Morpheus8 technology."

About InMode 

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

Press Contact:
Behrman Cesa Communications
[email protected]

Investor Contact:
MS-IR LLC
Miri Segal – Scharia
[email protected]

SOURCE InMode Ltd.

Modal title

Also from this source

InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025

InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025

InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial...

InMode to Report Second Quarter 2026 Financial Results on August 5, 2026, Expects Q2 Revenue Between $95.2M-$95.4M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

InMode to Report Second Quarter 2026 Financial Results on August 5, 2026, Expects Q2 Revenue Between $95.2M-$95.4M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial...

More Releases From This Source

Explore

Medical Equipment

Medical Equipment

Medical Pharmaceuticals

Medical Pharmaceuticals

Cosmetics and Personal Care

Cosmetics and Personal Care

Household, Consumer & Cosmetics

Household, Consumer & Cosmetics

News Releases in Similar Topics

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2026 Cision US Inc.